Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phase IV Reporting Improves In Year After FDA Issues Challenge To PhRMA

Executive Summary

The pharmaceutical industry appears to be doing a significantly better job in filing Phase IV study updates in a timely fashion, FDA's postmarketing database shows

You may also be interested in...



Phase IV Status Report: Fewer Open Studies, But More Overdue Reports

The pharmaceutical industry had 67% fewer drugs and biologics with open Phase IV commitments in fiscal year 2004 than the previous year, FDA's postmarketing database shows

Phase IV Status Report: Fewer Open Studies, But More Overdue Reports

The pharmaceutical industry had 67% fewer drugs and biologics with open Phase IV commitments in fiscal year 2004 than the previous year, FDA's postmarketing database shows

E-Prescribing To Improve Postmarketing Studies, CMS’ McClellan Predicts

Electronic prescribing systems can facilitate more efficient postmarketing clinical studies, CMS Administrator Mark McClellan said April 14

Related Content

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel